Lexicon Pharmaceuticals presents a highly speculative profile, with its commercial trajectory defined by extreme revenue volatility, as seen in the swing from $28.9M to $0.7M in subsequent quarters, and a deeply negative equity base driven by a cumulative -$2....
Price trend, volume and key moving averages
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.06-19.5% vs -$0.05 | $692,000-82.7% vs $4M |
Q2 2026 May 7, 2026 | -$0.00+93.5% vs -$0.04 | $21M+115.6% vs $10M |
Q2 2026 Mar 5, 2026 | -$0.04+42.9% vs -$0.07 | $5M+74.8% vs $3M |
Q4 2025 Nov 6, 2025 | -$0.04+42.9% vs -$0.07 | $14M+351.4% vs $3M |
Lexicon Pharmaceuticals (NASDAQ: LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executive Officer Dr. Mike Exton said the company is continuing its transition toward a cardiometabolic
Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:
Benchmark LXRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Lexicon Pharmaceuticals, Inc. (LXRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.86 | $826.2M | -13.29 | 60.24% | -101.08% | -39.72% | — | |
| $3.45 | $852.25M | -13.27 | 22.09% | -12.35% | -36% | — | |
| $118.51 | $12.72B | 144.52 | 12.79% | 6.61% | 8.37% | — | |
| $20.66 | $1.52B | 6.26 | 18.52% | 80.56% | 30.03% | — | |
| $137.34 | $8.83B | -67.00 | -89.41% | 29.4% | 12.03% | — | |
| $22.18 | $3.8B | 9.69 | 11.87% | 33.42% | 32.39% | — |
Lexicon Pharmaceuticals, Inc. (LXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Lexicon Pharmaceuticals, Inc. (LXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 7, 2026·SEC
May 6, 2026·SEC
Get notified when LXRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lexicon Pharmaceuticals, Inc. (LXRX) stock FAQ — growth, dividends, profitability & financials explained
Lexicon Pharmaceuticals, Inc. (LXRX) reported $41.5M in revenue for fiscal year 2025. This represents a 782% increase from $4.7M in 1999.
Lexicon Pharmaceuticals, Inc. (LXRX) grew revenue by 60.2% over the past year. This is strong growth.
Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $61.1M for fiscal year 2025.
Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity (ROE) of -39.7%. Negative ROE indicates the company is unprofitable.
Lexicon Pharmaceuticals, Inc. (LXRX) had negative free cash flow of $79.7M in fiscal year 2025, likely due to heavy capital investments.
